Prior studies have found that statin meds can help lower liver cancer risks, and new research suggests that at least one non-statin cholesterol drug can do the same. A team led by Katherine McGlynn of the U.S. National Cancer Institute looked at the health histories of almost 19,000 people tracked by the U.K.’s Clinical Practice Research Datalink.  About 3,700 of them developed liver cancer, and their medication use was compared to almost 15,000 others who did not get the disease. McGlynn’s team linked use of a non-statin form of cholesterol-lowering meds, called cholesterol absorption inhibitors, to 31% lower odds of developing liver cancer. Their findings were reported July 29 in the journal Cancer. The link held when the researchers accounted for other risk factors such as diabetes and liver disease status.  The study also re-confirmed that statins lower liver cancer risk by 35%. But the use of three other medicines used to lower cholesterol — fibrates, omega-3 fatty acids and niacin — did not seem to affect liver cancer risk, the research showed. Risks attributed to another drug type, bile acid sequestrants, were inconclusive. “As few studies have examined the effects of non-statin cholesterol-lowering drugs on liver cancer risk, the results of our study require replication in other populations,” McGlynn said in a journal news release. “If our findings are confirmed in other studies, however,…  read on >  read on >

People taking compounded versions of Ozempic have been overdosing on the drug, the U.S. Food and Drug Administration warns. These ODs typically are due to miscommunications or miscalculations regarding dosage, the FDA added. “Dosing errors have resulted from patients measuring and self-administering incorrect doses of the drug and health care providers miscalculating doses of the drug,” the FDA alert said. Health problems caused by overdoses of compounded semaglutide — the main ingredient in Ozempic and Wegovy — include severe nausea, vomiting and hypoglycemia, the FDA said. Other side effects include fainting, headache, migraine, dehydration, pancreatitis and gallstones. People who have a severe overdose might need to be kept for observation for an extended period, since the half-life of semaglutide is about a week, the FDA said. Drug compounding involves combining, mixing or altering drugs to create a medication tailored to the needs of an individual patient. “FDA is aware of compounded semaglutide products that are being marketed for weight loss,” the agency said. “Compounded drugs pose a higher risk to patients than FDA-approved drugs because compounded drugs do not undergo FDA premarket review for safety, quality or effectiveness.” “Compounded drugs should only be used for patients whose medical needs cannot be met by an available FDA-approved drug,” the agency added. Compounded semaglutide products can come in varying concentrations, and often are provided in multiple-use vials…  read on >  read on >

An additional cinnamon product sold in the United States has been found to contain high levels of lead, health officials are warning. In a health alert issued Thursday, the U.S. Food and Drug Administration said the ground cinnamon product, sold as El Servidor, joins a growing list of cinnamon products that have contained high levels of lead. Through testing, the cinnamon was found to have elevated lead levels at 20 parts per million. Although the FDA doesn’t set limits for lead levels in spices, the United Nations’ Food and Agriculture Organization has a proposed international safety standard of 2.5 parts per million of lead for bark spices like cinnamon, NBC News reported. The FDA noted that it has asked the distributor to recall the product. Lead in cinnamon products has become a growing problem: In March, the FDA warned about lead in fruit puree products sold at Dollar Tree, Family Dollar and other stores. Those products had levels of lead ranging from 2.03 to 3.4 parts per million. The cinnamon identified in the new alert was sold at a supermarket in New York City, although it’s unclear whether it was distributed more widely. Leigh Frame, director of integrative medicine at George Washington University School of Medicine and Health Sciences, told NBC News that the new recall was “alarming.” “We sort of assume things are safe until proven otherwise,” Frame…  read on >  read on >

The U.S. Food and Drug Administration on Thursday authorized the sale of the country’s best-selling e-cigarette. The agency’s decision only applies to several tobacco-flavored versions of the reusable product, sold as Vuse. In January 2023, the FDA rejected R.J. Reynold’s application for its more popular menthol flavor, but the company has challenged that ruling in court. Last month, the FDA granted competitor Njoy the first authorization for a menthol-flavored e-cigarette. That vaping brand is controlled by tobacco giant Altria. Despite the Vuse authorization, the FDA stressed that e-cigarettes are far from safe. “All tobacco products are harmful and potentially addictive,” the agency said in a new release announcing the decision. “Those who do not use tobacco products, especially young people, should not start.” In its decision, the agency noted that tobacco-flavored e-cigarettes do not hold the same appeal among youth that fruit- and candy-flavored vaping products do. “While FDA remains concerned about the risk of youth use of all e-cigarettes, youth are less likely to use tobacco‐flavored e-cigarette products compared to other flavors,” the agency said. “According to the 2023 National Youth Tobacco Survey, Vuse was among the most commonly reported brands used by middle and high school students currently using e-cigarette. However, only 6.4% of students who currently used e-cigarettes reported using tobacco‐flavored products.” To further discourage vaping among teens and adolescents, the FDA added that it…  read on >  read on >

4In a joint effort to curb the illegal sales of food products containing delta-8 THC, the U.S. Food and Drug Administration and the Federal Trade Commission said Tuesday they have warned five companies to stop marketing such products. Because the packaging for these THC edibles mimics that of popular snack foods, the FDA said it is concerned they can be easily mistaken for traditional foods, prompting accidental ingestion or overconsumption, especially by kids. “Inadequate or confusing labeling can result in children or unsuspecting adults consuming products with strong resemblance to popular snacks and candies that contain delta-8 THC without realizing it,” FDA Principal Deputy Commissioner Dr. Namandjé Bumpus said in a news release on the warnings. Delta-8 THC is the psychoactive ingredient in the cannabis sativa plant, of which marijuana and hemp plants are two varieties. The FDA said it has given the companies 15 working days to address the violations and prevent future ones. Last summer, the agencies issued similar warnings to six other companies selling products containing delta-8 THC, and those companies no longer have such products in stock, the agencies noted. A spokesperson for Earthly Hemps, one of the companies issued a warning Tuesday, told CNN that it has not sold any of the products this year. The other companies did not respond to a request for comment. The threat these “copycat” products pose is real: From…  read on >  read on >

Seventeen women in nine states have fallen ill after getting fake Botox shots, with 13 of them landing in the hospital and one requiring a ventilator, a new report warns. In the report, published Thursday by the U.S. Centers for Disease Control and Prevention, researchers provided alarming details of patients getting injections outside of a medical setting and then falling ill a few days later. In one instance, four women attended a gathering at a relative’s home in Tennessee to get Botox injected into their faces to smooth fine lines and wrinkles about three days before their symptoms began. An investigation later showed the injected product was counterfeit and was administered by a person who was not licensed to do so. “In some cases, providers were concerned about patients’ breathing to the point where they were admitting them to intensive care units to be able to monitor them more closely,” report author Dr. Christine Thomas, a medical director at the Tennessee Department of Health, told NBC News.  She called the situation a “perfect storm.” “We were seeing the injections happening in homes from people who weren’t licensed, and there was counterfeit product,” Thomas said. One of the most frightening cases detailed in the NBC News report involved a Colorado woman who got what she thought was Botox. Her vision soon blurred, and she became unusually…  read on >  read on >